Company: ANIX
Filing Date: 2025-09-10
Form Type: 10-Q
Source: 0001493152-25-013000
Chunk: 1

Company: Anixa Biosciences Inc
Filing Date: 2025-09-10
Form: 10-Q
Item: Part I, Item 1
Chunk 1
---
000 shares authorized; 32,822,109 and 32,196,862 shares issued and outstanding as of July
    31, 2025 and October 31, 2024, respectively 
     328  
     322 
  
    Additional
    paid-in capital 
     265,249  
     260,432 
  
    Accumulated
    deficit 
     (248,982) 
     (240,750)
  
    Treasury
    stock, 2,000 shares at cost as of October 31, 2024 
     -  
     (6)
  
    Total
    shareholders’ equity 
     16,595  
     19,998 
  
    Noncontrolling
    interest (Note 2) 
     (1,184) 
     (1,110)
  
    Total
    equity 
     15,411  
     18,888 

    Total
    liabilities and equity 
    $17,651  
    $21,591 

The
accompanying notes are an integral part of these condensed consolidated financial statements.

1

ANIXA
BIOSCIENCES, INC. AND SUBSIDIARIES

CONDENSED
CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)

(in
thousands, except per share data)

    2025  
    2024  
    2025  
    2024 

    For
    the three months ended  
    For
    the nine months ended 

    July
    31,  
    July
    31, 

    2025  
    2024  
    2025  
    2024 

    Revenue 
    $-  
    $-  
    $-  
    $- 

    Operating
    expenses: 

    Research
    and development expenses (including non-cash stock-based compensation expenses of $358, $462, $1,172 and $1,471, respectively) 
     1,055  
     1,925  
     3,929  
     4,920 
  
    General
    and administrative expenses (including non-cash stock-based compensation expenses of $497, $717, $1,727 and $2,228, respectively) 
     1,381